biomarkers
(19)
Ash
Ash (poweredbyash.com) is a New York-based health technology company that gives healthcare organizations a customizable, white-label platform for at-home diagnostic testing. Founded in 2019 as a direct-to-consumer sexual health testing service for the LGBTQ+ community, Ash pivoted to a B2B model that lets health plans, digital health companies and public health agencies launch branded testing programs across 100+ biomarkers in all 50 states. The company handles kit design, a vetted lab network, multilingual patient engagement, logistics and real-time reporting through one API, and has shipped more than 500,000 kits while helping organizations close care gaps and improve HEDIS and Star Ratings measures.
BostonGene
BostonGene is a Waltham, Massachusetts biotechnology company that applies AI-driven multiomics to cancer. Its Tumor Portrait platform integrates DNA and RNA sequencing with immune and tumor-microenvironment analysis into a single test, producing molecular profiles that help oncologists select therapies and help pharmaceutical partners design trials, identify biomarkers, and accelerate drug development. Founded in 2015 and led by CEO Andrew Feinberg, the company reached unicorn status in 2022.
Function Health
Function Health is an Austin-based membership platform that gives consumers direct access to 100-plus lab tests, optional full-body MRI scans, and AI-generated insights for a flat annual fee. Founded in 2021 and led by CEO Jonathan Swerdlin with physician co-founder Mark Hyman, the company sells a data-first, preventive approach to healthcare aimed at helping members catch problems early and track their biology over time. After a $298M Series B in November 2025 at a $2.5B valuation, Function has become one of the fastest-growing consumer health companies in the US.
GlycanAge
GlycanAge is a UK-registered, Croatian-founded longevity biotech that measures biological age by analyzing glycans - sugar molecules attached to immune-system antibodies. Built on roughly two decades of glycobiology research led by Professor Gordan Lauc, the company turns a finger-prick blood sample into a report on how fast a person is aging at the molecular level, plus a specialist consultation to guide lifestyle changes. It sells directly to consumers and is expanding its glycan biomarkers into hospitals and preventive-care systems.
Amprion
Amprion is a precision-diagnostics company using Seed Amplification Assay (SAA) technology to detect misfolded proteins - alpha-synuclein, amyloid-beta and tau - in cerebrospinal fluid, giving physicians and drug developers a biological readout of neurodegenerative disease years before symptoms fully emerge. Its flagship SAAmplify-aSYN test (formerly SYNTap) is the first commercially available validated alpha-synuclein SAA, carries an FDA Breakthrough Device Designation, and aims to replace symptom-based guesswork for Parkinson's, Lewy body dementia, Alzheimer's and multiple system atrophy with autopsy-grade certainty.
Aqtual, Inc.
Aqtual, Inc. is a Hayward, California precision medicine company that reads epigenetics, gene regulation and transcriptomics from a single blood draw. Its proprietary active-chromatin cell-free DNA (cfDNA) platform captures circulating chromatin to survey hundreds of thousands of regulatory sites, integrating DNA, epigenetic regulation and protein-DNA binding in one blood-based assay. The company is first commercializing a test that predicts which therapy will work for rheumatoid arthritis patients, with a broader pipeline spanning oncology, immunology, cardiovascular, metabolic and neurological disease. Aqtual has raised roughly $47M to date, including a $31M Series B in July 2025.
ARNA Genomics US Inc.
ARNA Genomics US Inc. is a San Francisco-based biotechnology company developing multiomics liquid-biopsy technology for early cancer detection. Its lead assay, ARNA Breast, analyzes cell-free DNA and plasma enzyme activity from a routine blood draw to flag early-stage breast cancer, with proof-of-concept studies reporting sensitivity above 90%. Founded in 2013 and led by CEO Egor Melnikov, the company raised a $3.5M Series A in 2020 to fund clinical validation.
Calibra Scientific Inc.
Calibra Scientific Inc. (Hangzhou Calibra Diagnostics Co., Ltd., 凯莱谱) is a clinical mass spectrometry and multi-omics company that builds the full stack of precision diagnostics - instruments, reagent kits, reference materials and central-lab services. Founded in 2016 by Hua-fen Liu, a veteran of SCIEX, Roche and Pfizer, and backed as a DIAN Diagnostics company, Calibra has launched the NMPA-registered CalQuant-S mass spectrometry system, 10+ Class II reagent kits and 300+ clinical assays, serving more than 20,000 hospitals and research institutions across China.
Solena
Solena is an agricultural biotechnology company that reads the microbiome of farm soil the way a doctor reads a blood panel. Farmers mail in a soil sample; Solena sequences the DNA of the microbes living in it, scores the soil's biological health with its MISS index, and its Prometheus platform turns that data into AI-driven prescriptions for what to apply, when, and how much. The goal is fewer synthetic inputs, healthier soil, better yields, and eligibility for carbon and regenerative-agriculture incentives.
Valar Labs
Valar Labs is a Palo Alto precision-oncology company building AI tests that read the pathology slides already made during routine cancer care. Its Vesta platform applies proprietary foundation models to standard H&E-stained tissue images to predict how individual patients will respond to therapy - starting with bladder cancer, where it forecasts whether a patient is likely to benefit from BCG treatment and stratifies the risk of recurrence and progression. Founded in 2021 by Stanford AI researchers, the company has raised $26M total and earned the FDA's first Breakthrough Device Designation for an AI digital-pathology prognostic test in bladder cancer.
Circular Genomics
Circular Genomics is a San Diego biotechnology company turning circular RNA (circRNA) into a new class of blood-based biomarkers for brain health. Spun out of the University of New Mexico in 2021, the company uses brain-enriched circRNAs that cross the blood-brain barrier and stay stable in whole blood to detect and predict neurological and psychiatric conditions, from Alzheimer's disease to major depressive disorder. Its goal is to replace guesswork in brain care with measurable, actionable data, starting with early Alzheimer's detection and SSRI treatment-response testing for depression.
MARAbio
MARAbio is a Salt Lake City precision-immunology company that built the first-ever blood test to identify Maternal Autoantibody Related Autism (MARA), a biological subtype of autism caused by a mother's own IgG autoantibodies crossing the placenta and binding fetal brain proteins. Founded on more than two decades of research by Dr. Judy Van de Water at the UC Davis MIND Institute, the company's MAR-Autism test screens mothers for specific autoantibody combinations linked to autism risk, and the company is now extending the science toward therapeutics that could neutralize those antibodies before they reach a developing brain.
Numen
Numen (formerly Cleancard) is a San Francisco biotech building rapid at-home cancer screens that read like a pregnancy test. By combining synthetic biology, machine learning, and computer vision, its platform detects multiple cancer biomarkers from a single urine sample in about 30 minutes, with no lab machinery required. Founded by Rhodes Scholars Thomas Carroll and Luca Springer, the company's first screens target prostate, bladder, and ovarian cancer, with a mission to drive cancer mortality toward zero.
Triveni Bio
Triveni Bio is a clinical-stage biotechnology company in Watertown, Massachusetts building first-in-class antibody therapeutics for immunological and inflammatory (I&I) diseases. Born from the 2023 merger of Amagma Therapeutics and Modify Therapeutics, the company pairs a genetics-informed approach with advanced antibody engineering to target root-cause biology rather than just downstream inflammation. Its lead program, TRIV-509, is a half-life-extended monoclonal antibody that inhibits active kallikreins 5 and 7 (KLK5/7) and is in a global Phase 2 proof-of-concept study for moderate-to-severe atopic dermatitis. Backed by roughly $223M across Series A and Series B rounds, Triveni aims to repair the skin barrier and break what it calls efficacy ceilings in dermatology and beyond.
Beacon Biosignals
Beacon Biosignals is a Boston-based neurotechnology company that pairs FDA-cleared wearable EEG hardware with AI to turn brain electrical activity - especially during sleep - into scalable, at-home neurodiagnostics. Its platform powers drug development, clinical trials, and precision medicine across neurology, psychiatry, and sleep medicine.
Evvy
Evvy is a precision women's health company building the first AI-powered vaginal healthcare platform around a CLIA-certified, at-home metagenomic vaginal microbiome test. Founded in 2021 by Stanford alums Priyanka Jain and Laine Bruzek, Evvy pairs state-of-the-art testing that screens for 700+ bacteria and fungi with clinician-reviewed results, personalized prescription treatment, and one-on-one health coaching. By generating one of the largest datasets on female biomarkers, Evvy aims to close the gender health gap - starting with conditions like bacterial vaginosis that have been chronically under-researched.
Prenuvo
Prenuvo runs a chain of clinics built around a 60-minute whole-body MRI designed to spot cancer, aneurysms and hundreds of other conditions before symptoms show up. Founded by Andrew Lacy and radiologist Raj Attariwala, the company is trying to drag American healthcare from reactive to preventive, one scan at a time.
ArteraAI
ArteraAI is a precision medicine company building multimodal AI tests that personalize cancer therapy. Its flagship ArteraAI Prostate Test is the first AI-enabled predictive and prognostic biomarker recommended in the NCCN Guidelines for localized prostate cancer, validated across five Phase 3 trials.
Vivoo
Vivoo is a San Francisco-based health tech company that makes at-home urine test strips analyzed via smartphone camera. Founded in 2017, the company offers a wellness platform that measures 8+ biomarkers — including hydration, vitamins, minerals, pH, ketones, and oxidative stress — and delivers personalized nutrition and lifestyle recommendations through a free mobile app. Backed by $19.4M in funding led by Tim Draper, Vivoo is sold at Target, Walmart, and Sam's Club, and has expanded to 100+ countries with a focus on making lab-grade health insights accessible to everyday consumers.